NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ('ANEW' or 'the Company') (OTCPK: LEAS) a US-based biotechnology company ('ANEW') focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

纽约，2024年3月4日/PRNewswire/--ANEW MEDICAL，INC.（“ANEW”或“the Company”）（OTCPK:LEAS）是一家总部位于美国的生物技术公司（“ANEW”），专注于开发基于细胞和基因的治疗方法，以影响衰老和与年龄有关的疾病，宣布该公司已在中国获得授权并颁发了专利，编号CN 117126829 A，用于使用新的Klotho蛋白和Klotho基因传递和表达系统治疗认知，记忆和神经退行性疾病。

This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid for all patent costs associated with obtaining –the patent..

该知识产权由位于西班牙巴塞罗那的巴塞罗那奥诺玛大学（UAB）和加泰罗尼亚研究所（ICREA）在全球范围内独家授权，并重新支付了与获得专利相关的所有专利费用。。

Dr. Joseph Sinkule, the Founder and CEO of ANEW stated 'Obtaining a patent in China was difficult but important to our global product development programs in neurodegenerative diseases. The aging population in China is affected by the same age-related diseases we are fighting in the US and Europe. ANEW plans to obtain patents in Hong Kong and other Asian markets and seek to establish a distributorship in these markets with companies in Asia that can market and sell our products'..

ANEW创始人兼首席执行官约瑟夫·辛克尔（JosephSinkule）博士表示，“在中国获得专利很困难，但对我们在神经退行性疾病方面的全球产品开发计划很重要。中国的人口老龄化受到我们正在美国和欧洲抗击的与年龄有关的疾病的影响。ANEW计划在香港和其他亚洲市场获得专利，并寻求在这些市场与能够营销和销售我们产品的亚洲公司建立分销关系。。

In May 2023, ANEW announced its proposed merger with a special purpose acquisition company ('SPAC') called Redwoods (NASDAQ: RWOD) ('RWOD' or 'Redwoods'). At closing, anticipated to take place in March 2024, we expect ANEW to be listed on NASDAQ. The CFO of RWOD and a member of the RWOD Board, Mr. Edward Cong Wang, will join the ANEW Board of Directors on the board of the combined company..

2023年5月，新公司宣布了与一家名为Redwoods（纳斯达克股票代码：RWOD）（“RWOD”或“Redwoods”）的特殊目的收购公司（“SPAC”）的拟议合并。预计在2024年3月交割时，我们预计将在纳斯达克重新上市。RWOD首席财务官和RWOD董事会成员Edward Cong Wang先生将加入合并公司董事会的新董事会。。

About ANEW MEDICAL, INC. - ANEW MEDICAL, INC. (OTC: LEAS) is a technology and medical product development company focused on the development of therapeutics and diagnostics for a broad range of life-threating disease indications. The Company has offices in the US and in Spain. ANEW's current portfolio consists of three platforms - generic oncology drugs that are in short supply in the US, Phase 3 ready biosimilar biologics targeting cancer and autoimmune diseases, and its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics..

关于ANEW MEDICAL，INC.-ANEW MEDICAL，INC.（OTC:LEAS）是一家技术和医疗产品开发公司，专注于开发各种威胁生命的疾病适应症的治疗和诊断方法。该公司在美国和西班牙设有办事处。ANEW目前的投资组合包括三个平台-美国供应短缺的通用肿瘤药物，针对癌症和自身免疫性疾病的3期生物仿制药，以及使用DNA和RNA作为治疗和诊断的专有基因治疗计划。。

Important Information about the Proposed Business Combination and Where to Find It

关于拟议企业合并的重要信息以及在哪里可以找到它

This press release relates to a proposed transaction between Redwoods and ANEW. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本新闻稿涉及红杉和ANEW之间拟议的交易。本新闻稿不构成出售或交换任何证券的要约，也不构成邀请购买或交换任何证券的要约，在任何司法管辖区内，如果该等要约、出售或交换在根据任何该等司法管辖区的证券法注册或取得资格之前是非法的，则不存在任何证券销售。

In connection with the proposed business combination, Redwoods, ANEW and/or a successor entity of the transaction has filed relevant materials with the SEC, including a registration statement on Form S-4 containing a proxy statement/prospectus (the 'Registration Statement'). The Registration Statement includes a proxy statement/prospectus to be distributed to holders of Redwoods's common stock in connection with Redwoods's solicitation of proxies for the vote by Redwoods's stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to ANEW's stockholders in connection with the proposed business combination.

关于拟议的企业合并，Redwoods、ANEW和/或交易的继承实体已向SEC提交了相关材料，包括S-4表格上的登记声明，其中包含一份委托书/招股说明书（“登记声明”）。登记声明包括一份委托书/招股说明书，该委托书/招股说明书将分发给Redwoods普通股持有人，与Redwoods就拟议交易和登记声明中描述的其他事项向Redwoods股东征求代理人投票有关，以及与拟议企业合并相关的向新股东发行证券的招股说明书。

The Registration Statement has been filed and declared effective, and Redwoods [has mailed] a definitive proxy statement to its stockholders..

登记声明已存档并宣布生效，红杉（Redwoods）已向其股东邮寄了一份最终委托书。。

Before making any voting or investment decision, investors and security holders and other interested parties are urged to read the Registration Statement, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about Redwoods, ANEW and the proposed business combination.

在做出任何投票或投资决定之前，投资者、证券持有人和其他利益相关方应仔细阅读登记声明、任何修订以及提交给SEC的任何其他文件，因为这些文件将包含有关红杉、新公司和拟议企业合并的重要信息。

Copies of these documents may be obtained free of charge at the SEC's website at www.sec.gov..

这些文件的副本可以在美国证券交易委员会的网站www.SEC.gov上免费获得。。

The documents filed by Redwoods with the SEC also may be obtained free of charge upon written request to Redwoods at c/o Redwoods Acquisition Corp., 1115 Broadway 12th Floor, New York, NY 10010. The documents filed by ANEW or any successor entity of the transaction with the SEC also may be obtained free of charge upon written request to ANEW at 13576 Walnut Street, Suite A, Omaha, NE 68144 USA..

Redwoods向SEC提交的文件也可以在收到Redwoods的书面请求后免费获得，地址为Redwoods Acquisition Corp.，1115 Broadway 12th Floor，New York，NY 10010。如果向ANEW发出书面请求，也可以免费获得ANEW或该交易的任何继承实体向SEC提交的文件，地址为13576 Walnut Street，Suite A，Omaha，NE 68144 USA。。

Participants in the Solicitation

征集参与者

Redwoods and ANEW and their respective directors and executive officers may be deemed participants in the solicitation of proxies from Redwoods' stockholders with respect to the proposed business combination under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain of Redwoods' executive officers and directors in the solicitation by reading Redwoods' Registration Statement and other relevant materials filed with the SEC in connection with the proposed business combination when they become available.

Redwoods和ANEW及其各自的董事和执行官可能被视为根据美国证券交易委员会（SEC）的规则就拟议的企业合并向Redwoods股东征集代理人的参与者。证券持有人可能会获得有关名称、隶属关系，通过阅读Redwoods的注册声明和提交给SEC的与拟议企业合并有关的其他相关材料，以及Redwoods的某些高管和董事在招标中的利益。

Information about Redwoods' directors and executive officers and their ownership of Redwoods common stock is set forth in its prospectus related to its initial public offering dated April 1, 2022. Other information regarding the interests of Redwoods' participants in the proxy solicitation, which in some cases, may be different than those of their stockholders generally, will be set forth in the Registration Statement relating to the proposed business combination when it becomes available.

有关红杉董事和高管及其对红杉普通股所有权的信息，请参见其与2022年4月1日首次公开募股相关的招股说明书。有关红杉参与委托书征集的其他信息（在某些情况下可能与股东的利益不同）将在与拟议企业合并相关的登记声明中予以规定。

These documents can be obtained free of charge at the SEC's web site at www.sec.gov..

这些文件可以在美国证券交易委员会的网站www.SEC.gov上免费获得。。

ANEW and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Redwoods in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the Registration Statement for the proposed business combination..

ANEW及其董事和执行官也可能被视为红杉股东就拟议的企业合并征集代理人的参与者。该等董事和高级管理人员的名单及其在拟议企业合并中的权益信息将包含在拟议企业合并的登记声明中。。

Non-Solicitation

不招揽

This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本新闻稿并非任何证券或拟议企业合并的代理声明或代理、同意或授权的征求。本新闻稿也不构成出售或招揽购买任何证券的要约，也不构成在任何州或司法管辖区内出售任何证券，在任何州或司法管辖区内，根据任何该等司法管辖区的证券法登记或取得资格之前，该等要约、招揽或出售将是非法的。

No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom..

除非通过符合经修订的《1933年证券法》第10节要求的招股说明书或豁免书，否则不得进行证券发行。。

Forward-Looking Statements - This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan', 'expect', 'anticipate', 'may', 'might', 'will', 'should', 'project', 'believe', 'estimate', 'predict', 'potential', 'intend', or 'continue', or other words or terms of similar meaning.

前瞻性声明-本新闻稿包含前瞻性声明。除历史事实陈述外，所有陈述均为“前瞻性陈述”，包括与未来事件有关的陈述。在某些情况下，前瞻性陈述可以通过术语来识别，例如“计划”、“预期”、“预期”、“可能”、“可能”、“将”、“应该”、“项目”、“相信”、“估计”、“预测”、“潜在”、“打算”或“继续”，或其他具有类似含义的单词或术语。

These statements include, without limitation, statements related to research, pr-clinical data, plans for future development, and the potential of a drug development candidate. These forward-looking statements are based on our current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties.

这些陈述包括但不限于与研究相关的陈述，pr临床数据，未来发展计划以及药物开发候选人的潜力。这些前瞻性陈述基于我们目前的计划、目标、估计、期望和意图，固有地涉及重大风险和不确定性。

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a results of these risks and uncertainties, which include, without limitation, risks and uncertainties with the COVID-19 pandemic and its impact on the Company's clinical plans and business strategy, risks and uncertainties associated with product development and clinical success thereof, the uncertainties of regulatory approvals, and manufacturing and supply risks, other risks and uncertainties affecting the Company and its research and development programs as set forth in its SEC filings.

由于这些风险和不确定性，实际结果和事件发生的时间可能与此类前瞻性声明中预期的结果存在重大差异，这些风险和不确定性包括但不限于新型冠状病毒大流行的风险和不确定性及其对公司临床计划和业务战略的影响，与产品开发及其临床成功相关的风险和不确定性，监管批准的不确定性，制造和供应风险，影响公司及其研究和开发计划的其他风险和不确定性，如SEC文件所述。

Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof.

公司目前不知道的其他风险和不确定性也可能影响公司的前瞻性陈述，并可能导致实际结果和事件发生的时间与预期有重大差异。本文中的前瞻性陈述仅在本文日期作出。

The Company undertakes no.

本公司承诺。

Investor Contact - Info@anewmeds.com

投资者联系方式-Info@anewmeds.com

ANEW MEDICAL, INC. – U.S. Phone (402) 239-5556

ANEW MEDICAL，INC.–美国电话（402）239-5556

View original content:https://www.prnewswire.com/news-releases/anew-medical-announces-key-patent-issued-in-china-to-protect-klotho-protein-and-gene-delivery-systems-302077883.html

查看原始内容：https://www.prnewswire.com/news-releases/anew-medical-announces-key-patent-issued-in-china-to-protect-klotho-protein-and-gene-delivery-systems-302077883.html

SOURCE ANEW MEDICAL, INC.

SOURCE ANEW MEDICAL公司。

Company Codes: NASDAQ-NMS:RWOD

公司代码：NASDAQ-NMS：RWOD